When lesions are found after ovarian cancer surgery, it is necessary to promptly choose the treatment plan such as surgery, chemotherapy or anti-angiogenesis under the guidance of doctors, and chemotherapy can choose paclitaxel, carboplatin and so on. When lesions are found in ovarian cancer patients after surgery, recurrence is generally considered. For patients with platinum-sensitive recurrence, the first step is to evaluate whether they can be operated again, and patients who are operated or cannot be operated for tumor reduction should still be treated with platinum-containing combination chemotherapy, such as carboplatin+paclitaxel, carboplatin+docetaxel, and carboplatin+gemcitabine, etc., with an effective rate of 33%~80%. For patients with platinum-resistant relapse, non-platinum single-agent chemotherapy is preferred, such as liposomal doxorubicin, albumin-bound paclitaxel, docetaxel, etc., or combined with anti-angiogenic drugs, such as bevacizumab, with an effective rate of 10%~25%. In addition, the prognosis of ovarian cancer can be improved through “early detection, early diagnosis and early treatment”, so once diagnosed, the treatment should be standardized in time. Please strictly follow the doctor’s prescription for drug treatment and do not use drugs on your own.